TCGA-AN-A03Y-01A-21R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 0
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.540
- MYC_TARGETS_V2+0.470
- MYC_TARGETS_V1+0.450
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.310
- DNA_REPAIR+0.300
- PANCREAS_BETA_CELLS+0.270
- OXIDATIVE_PHOSPHORYLATION+0.240
- MTORC1_SIGNALING+0.190
- SPERMATOGENESIS+0.150
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.470
- TGF_BETA_SIGNALING-0.450
- TNFA_SIGNALING_VIA_NFKB-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- KRAS_SIGNALING_UP-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- ANGIOGENESIS-0.350
- HYPOXIA-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
- INFLAMMATORY_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.912 |
| 2 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.899 |
| 3 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.898 |
| 4 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.896 |
| 5 | BS_M84H3KXA | medulloblastoma | — | 0.896 |
| 6 | TCGA-44-7667-01A-31R-2066-07 | — | cohortA3 | 0.895 |
| 7 | TCGA-4Z-AA87-01A-11R-A39I-07 | — | — | 0.894 |
| 8 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.892 |
| 9 | BS_YETBN0RQ | medulloblastoma | — | 0.891 |
| 10 | SRR4195684 | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |